Influence of dietary hydrogenated palm oil supplementation on serum biochemistry and progesterone levels in dairy goats

The aim of this research was to investigate the influence of hydrogenated palm oil (HPO) added to a dairy goat diet on serum biochemistry and progesterone levels. Thirty pregnant Cilentana dairy goats were equally divided into 2 groups (control [CTR] and HPO groups). After kidding, concentrated feed for both groups was gradually increased up to 400 g/(animal$d), and the HPO group received 50 g/(animal$d) of HPO. Supplementation with HPO significantly increased cholesterol levels (mg/dL, 63.80 vs. 54.68 at 30 d, P 0.05; 78.20 vs. 58.00 at 60 d, P 0.05; 83.80 vs. 57.83 at 120 d, P 0.01) compared with the CTR group although no significant differences were detected for liver and kidney function indicators. Moreover, other biochemical parameters were not affected by HPO supplementation thus suggesting no change occurred in lipid and protein metabolism. Furthermore, a significant correlation was found be- tween progesterone levels and serum cholesterol (r 1⁄4 0.65, P 0.01) although these were not signifi- cantly higher in HPO supplemented goats. The dose and time of HPO supplementation appears critical as regards assessing the limits between the risks and benefits of HPO supplementation in dairy goats. At the tested dose, HPO was well tolerated by the animals and may represent a useful tool to increase energy availability during highly demanding periods

359 Gold-alloy tip electrode: A new "deep lesion" technology for catheter ablation?

n/

Assessment of genetically modified soybean 40‐3‐2 for renewal authorisation under Regulation (EC) No 1829/2003 (application EFSA‐GMO‐RX‐023)

Following the submission of application EFSA-GMO-RX-023 under Regulation (EC) No 1829/2003 from Bayer Agriculture BV on behalf of Bayer CropScience LP, the Panel on Genetically Modified Organisms of the European Food Safety Authority was asked to deliver a scientific risk assessment on the data submitted in the context of the renewal of authorisation application for the herbicide-tolerant genetically modified soybean 40-3-2, for food and feed uses, excluding cultivation within the European Union. The data received in the context of this renewal application contained post-market environmental monitoring reports, a systematic search and evaluation of literature, updated bioinformatic analyses, and additional documents or studies performed by or on behalf of the applicant. The GMO Panel assessed these data for possible new hazards, modified exposure or new scientific uncertainties identified during the authorisation period and not previously assessed in the context of the original application. Under the assumption that the DNA sequence of the event in soybean 40-3-2 considered for renewal is identical to the sequence of the originally assessed event, the GMO Panel concludes that there is no evidence in renewal application EFSA-GMO-RX-023 for new hazards, modified exposure or scientific uncertainties that would change the conclusions of the original risk assessment on soybean 40-3-2

Scientific Opinion of Flavouring Group Evaluation 410 (FGE.410): 4’,5,7-trihydroxyflavanone from chemical group 25 (phenol derivatives containing ring-alkyl, ring-alkoxy, and side-chains with an oxygenated functional group)

Publisher PD

Glycerol as a Superior Electron Source in Sacrificial H₂ Production over TiO₂ Photocatalyst

Biodiesel fuel (BDF) has gained much attention as a new sustainable energy alternative to petroleum-based fuels. BDF is produced by transesterification of vegetable oil or animal fats with methanol along with the co-production of glycerol. Indeed, transesterification of vegetable oil (136.5 g) with methanol (23.8 g) was performed under heating at 61°C for 2 h in the presence of NaOH (0.485 g) to produce methyl alkanoate (BDF) and glycerol in 83.7 and 73.3% yields, respectively. Although BDF was easily isolated by phase separation from the reaction mixture, glycerol and unreacted methanol remained as waste. In order to construct a clean BDF synthesis, the aqueous solution of glycerol and methanol was subjected to sacrificial H2 production over a Pt-loaded TiO2 catalyst under UV irradiation by high-pressure mercury lamp. H2 was produced in high yield. The combustion energy (ΔH) of the evolved H2 reached 100.7% of the total ΔH of glycerol and methanol. Thus, sacrificial agents such as glycerol and methanol with all of the carbon attached to oxygen atoms can continue to serve as an electron source until their sacrificial ability was exhausted. Sacrificial H2 production will provide a promising approach in the utilization of by-products derived from BDF synthesis

Desmopressin after cardiac surgery in bleeding patients : A multicenter randomized trial

Background: Previous studies showed that desmopressin decreases post-operative blood loss in patients undergoing cardiac surgery. These studies were small and never studied the effect of desmopressin in patients with active bleeding. Objective of the study was to determine whether desmopressin reduces red blood cells transfusion requirements in patients with active bleeding after cardiac surgery who had been pre-treated with tranexamic acid. Methods: This multicenter, randomized, double-blind, placebo-controlled, parallel-group study randomized elective patients with bleeding after cardiac surgery despite pre-treatment with tranexamic acid, to receive placebo (saline solution) or a single administration of desmopressin (0.3 \u3bcg/kg in saline solution). The primary endpoint was the number of patients requiring red blood cells transfusion after randomization and during hospital stay. Secondary end points were: blood loss from chest tubes during the first 24 h after study drug administration, hours of mechanical ventilation, intensive care unit stay, and in-hospital mortality. Results: The study was interrupted after inclusion of 67% of the planned patients for futility. The number of patients requiring red blood cells transfusion after randomization was 37/68 (54%) in desmopressin group and 33/67 (49%) in placebo group (P = 0.34) with no difference in blood loss: 575 (interquartile 422-770) ml in desmopressin group and 590 (476-1013) ml in placebo group (P = 0.42), mechanical ventilation, intensive care unit stay or mortality. Conclusions: This multicenter randomized trial demonstrated that, in patients pre-treated with tranexamic acid, desmopressin should not be expected to improve treatment of patients who experience bleeding after cardiac surgery